作者: Thomas Stricker , Daniel V.T. Catenacci , Tanguy Y. Seiwert
DOI: 10.1053/J.SEMINONCOL.2011.01.013
关键词:
摘要: Cancers arise as a result of an accumulation genetic aberrations that are either acquired or inborn. Virtually every cancer has its unique set molecular changes. Technologies have been developed to study cancers and derive characteristics increasingly implications for clinical care. Indeed, the identification key (molecular drivers) may ultimately translate into dramatic benefit patients through development highly targeted therapies. With increasing availability newer, more powerful, cheaper technologies such multiplex mutational screening, next generation sequencing, array-based approaches can determine gene copy numbers, methylation, expression, others, well sophisticated interpretation high-throughput information using bioinformatics tools like signatures predictive algorithms, will routinely be characterized in near future. This review examines background clinicians physician-scientists need interpret order develop better, personalized treatment strategies.